Cingulate Inc. Stock Price

NasdaqCM:CING Community·US$21.2m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
7 Fair Values set on narratives written by author

Create a narrative

CING Share Price Performance

US$3.70

-0.13 (-3.39%)

US$3.70

-0.13 (-3.39%)

US$3.70

Tue, 4 Nov 25

Share PriceUS$3.70

CING Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

High growth potential with moderate risk.

5 Risks

2 Rewards

View Full Analysis

Cingulate Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -3.20
: 0%
: 0%
: 93.2%

View Full Analysis

About CING

Founded: 2012
Employees: 13
CEO: Jennifer Callahan
WebsiteView website: www.cingulate.com

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.